Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients with Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL.

Arjun Majithia,Deepak L. Bhatt,Allon N. Friedman,Michael Miller,Ph. Gabriel Steg,Eliot A. Brinton,Terry A. Jacobson,Steven B. Ketchum,Rebecca A. Juliano,Lixia Jiao,Ralph T. Doyle,Craig Granowitz,Matthew J. Budoff,R. Preston Mason,Jean-Claude Tardif,William E. Boden,Christie M. Ballantyne

Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients with Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL.

2021

Arjun Majithia
Deepak L. Bhatt
Allon N. Friedman
Michael Miller
Ph. Gabriel Steg
Eliot A. Brinton
Terry A. Jacobson
Steven B. Ketchum
Rebecca A. Juliano
Lixia Jiao
Ralph T. Doyle
Craig Granowitz
Matthew J. Budoff
R. Preston Mason
Jean-Claude Tardif
William E. Boden
Christie M. Ballantyne

Background: Chronic kidney disease is associated with adverse outcomes among patients with established cardiovascular disease (CVD) or diabetes. Commonly used medications to treat CVD are less effe...

Keywords:

Kidney disease
Disease
Medicine
Range (biology)
adverse outcomes
Renal function
in patient
Internal medicine
Diabetes mellitus

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations